Under Robert F. Kennedy Jr., federal officials may withdraw an endorsement for the vaccine in younger children.

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

This was the stock's second consecutive day of gains.

The Food and Drug Administration is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy children under 5 years old, a move that would add another barrier for parents ...

The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy ...

Shares of the biotech were up 4.3% in premarket trading, after it also beat Wall Street expectations for second-quarter ...

Novavax (NVAX) stock gains as the company beats Q2 revenue estimates and raises its 2025 revenue outlook, buoyed by ...

Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

The federal government’s move to pull hundreds of millions of dollars in funding for mRNA vaccines could be a shot in the arm ...

Discover Novavax's Q2 2025 earnings insights: raised revenue targets, cost reductions, key partnerships with Sanofi & Takeda, and progress in ...